AION Labs
AION Labs is an Israel-based venture studio, founded in 2021, that builds and funds AI-driven biotech startups in partnership with AstraZeneca, Merck, Pfizer, Teva, and AWS, providing pre-seed capital, pharma mentorship, and cloud infrastructure to portfolio companies focused on drug discovery and development.
- Company typePrivate
- Founded2021
- HeadquartersRehovot, Israel
- Headcount1–10
- GTM typeB2B
- OfferingServices
What AION Labs does
AION Labs is an Israel-based venture studio founded in 2021 in Rehovot that creates and funds AI-driven biotech startups targeting pharmaceutical R&D. The studio is structured as a unique partnership uniting four competing global pharmaceutical companies (AstraZeneca, Merck KGaA, Pfizer, Teva), technology partner AWS, and venture capital firms (Israel Biotech Fund, Amiti Ventures). Through a co-development model, AION Labs identifies pharma-defined unmet needs via open innovation challenges, recruits founders, and provides pre-seed funding of at least $500,000 per year for up to four years plus $100,000 in AWS cloud credits per startup, along with mentorship and operational support.
The studio's portfolio spans nine companies across diverse therapeutic and platform modalities, including antibody design (CombinAble, DenovAI), molecular glues (TenAces), RNA targeting (Renasis Bio), gene editing (Cassidy Bio), cancer therapeutics (Cellyrix), epiproteomics (Promise Bio), small molecule discovery (ProPhet), and pre-clinical safety analysis (Omec). AION Labs does not sell commercial products or services; its economics are built on equity stakes in portfolio companies, with returns realized through follow-on funding rounds and exits — exemplified by the January 2026 acquisition of CombinAble by Insitro, which also established Insitro's first R&D center in Israel.
The core technology proposition rests on a federated data platform that enables pre-competitive collaboration among rival pharma companies while maintaining data isolation, supported by AWS cloud infrastructure and hands-on R&D mentorship. Portfolio companies apply generative AI (diffusion models, LLMs), ML optimization, predictive analytics, and agentic architectures to drug discovery challenges. Portfolio funding milestones include Promise Bio's $8.3M seed and Cassidy Bio's $8M seed round, signaling market validation of the studio's company-building approach.
AION Labs firmographics
Firmographics- Name
- AION Labs
- Legal name
- AION Labs
- Website
- https://aionlabs.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AION Labs is an Israel-based venture studio, founded in 2021, that builds and funds AI-driven biotech startups in partnership with AstraZeneca, Merck, Pfizer, Teva, and AWS, providing pre-seed capital, pharma mentorship, and cloud infrastructure to portfolio companies focused on drug discovery and development.
- Ownership category
- akta.pro rank
AION Labs industry classification
Industry- Product category
- Pharmaceutical AI Venture Studio / Biotech Incubation
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Management Consulting Services (54161)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372), Services-Management Consulting Services (8742)
- akta.pro primary industry
- Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Foundation Model Developers (LLM/Multimodal Model Labs) (HDAAACAA), AI/ML Engineering & Model Development Services (BPAEAHAF)
Keywords
Where AION Labs is headquartered
LocationHeadquarters
- HQ city
- Rehovot
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
AION Labs business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Revenue model
- Equity stakes in portfolio companies: AION Labs generates returns through equity ownership in the startups it creates and funds. As a venture studio, it takes equity in newly formed companies in exchange for pre-seed funding, pharma mentorship, operational support, and cloud credits. Returns are realized through follow-on funding rounds, M&A exits (e.g., CombinAble.AI acquired by Insitro), and potential IPOs.
- Strategic partnership fees: Pharma partners (AstraZeneca, Merck, Pfizer, Teva) and technology partners (AWS) provide funding, in-kind resources (cloud credits, mentorship time), and access to data/infrastructure in exchange for early access to innovations and co-ownership in the venture studio model.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
AION Labs product offering
Product offeringCore offering
AION Labs is a venture studio that identifies unmet pharmaceutical R&D needs defined by partner pharma companies (AstraZeneca, Merck, Pfizer, Teva), recruits entrepreneurial founders through open innovation challenges, and builds AI-driven biotech startups by providing pre-seed funding ($500K+/year for up to 4 years), AWS cloud infrastructure and credits ($100K), pharma mentorship, and end-to-end operational support from ideation through growth. The studio takes equity stakes in the resulting companies and captures returns via follow-on funding rounds, M&A exits, and potential IPOs.
Product overview
AION Labs operates as a venture studio that builds and grows AI-powered biotech companies through a co-development model. The company unites competing pharmaceutical companies (AstraZeneca, Merck, Pfizer, Teva) with technology partners (AWS, Israel Biotech Fund, Amiti Ventures) to address pharma-defined unmet needs. The portfolio includes multiple portfolio companies at various stages: DenovAI and Promise Bio are active companies developing AI platforms for protein design and epiproteomics; TenAces and CombinAble focus on molecular glue and antibody optimization; Renasis Bio, Cassidy Bio, Cellyrix, and ProPhet represent newer ventures in RNA targeting, gene editing, cancer therapeutics, and small molecule discovery respectively; Omec addresses clinical trial prediction; CombinAble was acquired by Insitro. The model provides startups with early access to pharma insights, R&D validation, mentorship, and funding.
Differentiator
Problem solved
Functional benefit
Products and services
- AION Labs Venture Studio Program
- CombinAble (CombinAble.AI)
Quantifiable outcome
- 9 companies launched in over three years with multiple pharma pilots and collaborations
- +3 more outcomes
Companies that use AION Labs
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
AION Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature2 records
AION Labs partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Insitro (acquirer of CombinAble.AI)coreInsitro, a US-based AI-drug discovery unicorn, acquired CombinAble.AI (an AION Labs portfolio company), establishing their first R&D center in Israel based on the CombinAble team. This represents the first Israeli exit for an AI pharma startup.
- Promise Bio (Portfolio Company)corePromise Bio emerged from stealth with $8.3M seed investment led by Awz Ventures, with participation from AstraZeneca and Pfizer via AION Labs. Promise Bio develops a computational epiproteomics and AI platform for precision medicine in immune-mediated diseases.
- AstraZenecacoreAstraZeneca is a founding pharma partner of AION Labs, providing R&D expertise, mentorship for portfolio companies, validation of unmet needs, and early adoption of AI-driven drug discovery solutions. AstraZeneca participates on the Board of Directors and Investment Committee.
- Merck KGaAcoreMerck KGaA (known as EMD Serono in North America) is a founding pharma partner contributing R&D expertise, mentorship, and validation capabilities for AI-driven pharma startups created through the AION Labs venture studio.
- PfizercorePfizer is a founding pharma partner providing R&D validation, mentorship from its global teams, and early commercial engagement opportunities for startups developing AI solutions for drug discovery and development.
- Teva PharmaceuticalscoreTeva Pharmaceuticals is a founding pharma partner and the Israeli anchor pharma company in AION Labs. Teva has led specific challenge calls, including the Entrepreneur in Residence program for AI-driven clinical trial control arms, and contributes R&D and operational expertise.
- AWS (Amazon Web Services)coreAWS provides cloud infrastructure, $100,000 in cloud credits per startup, and technology mentorship to help portfolio companies design platform architectures. AWS joined the pharma consortium and IBF in launching the AI therapeutics lab.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
AION Labs competitors and assessment
Company assessmentDirect peers
- IndieBio: Biotech accelerator providing seed funding, mentorship, and lab infrastructure to science-driven startups. While IndieBio is broader (synthetic biology, food tech, etc.), its venture-building model for early-stage biotech is directly comparable to AION Labs' studio approach.
- Petri (SRI International): Biotech startup accelerator historically focused on launching early-stage life science and pharma ventures from research institutions. Direct peer in the venture-builder-for-biotech category, though smaller in pharma-specific AI focus compared to AION Labs.
- BioMed X: Independent biomedical research venture builder operating a challenge-based recruitment model similar to AION Labs, partnering with global pharma (Boehringer Ingelheim, Janssen, etc.) to launch biotech ventures. Both operate crowd-sourced idea competitions and co-development pipelines bridging pharma R&D with academic talent.
Broad incumbents
- Flagship Pioneering: The largest and most established biotech venture studio, having created dozens of companies including Moderna. Operates a similar 'venture creation' model but at vastly greater scale and capital base. AION Labs is a smaller, regionally-focused analogue operating in the AI-pharma niche.
- Insitro: US-based AI-drug discovery unicorn and acquirer of AION Labs portfolio company CombinAble.AI. Insitro operates as a vertically integrated AI pharma company rather than a venture studio, but it represents a potential exit path and strategic partner for AION Labs portfolio companies.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning. Operates a single integrated platform rather than a multi-venture studio model, but addresses the same pharma R&D transformation problem and competes for similar AI-pharma talent and partnerships.
Regional players
- Israel Biotech Fund: Founding VC partner of AION Labs and a regional biotech-focused venture capital firm. While IBF is a financial partner rather than a peer in the strictest sense, it operates in the same Israel biotech ecosystem and provides comparable venture-building expertise and follow-on capital.
Emerging players
- Celsius Therapeutics: AI-driven therapeutics company applying single-cell genomics and machine learning to drug discovery, with direct overlap to AION Labs portfolio company Cellyrix. Comparable in scale and stage as an emerging AI-pharma venture.
- Atomwise: AI drug discovery company using structure-based deep learning for small molecule design. Direct overlap with AION Labs portfolio companies like ProPhet and TenAces, and similar pharma partnership model with companies including Sanofi and Eli Lilly.
- Xaira Therapeutics: AI-native drug discovery company founded in 2023 with significant capital from ARCH Venture Partners. Competes for the same AI-pharma talent and pharma partnerships that AION Labs' venture studio model is built around, though Xaira operates as a single company rather than a studio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
AION Labs social profiles
Digital presenceAION Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
AION Labs leadership team
Management profileNumber of profiles
Profiles7 records
AION Labs subsidiaries and ownership
Company hierarchySubsidiaries9 records
AION Labs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AION Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AION Labs
What does AION Labs do?
AION Labs is a venture studio that identifies unmet pharmaceutical R&D needs defined by partner pharma companies (AstraZeneca, Merck, Pfizer, Teva), recruits entrepreneurial founders through open innovation challenges, and builds AI-driven biotech startups by providing pre-seed funding ($500K+/year for up to 4 years), AWS cloud infrastructure and credits ($100K), pharma mentorship, and end-to-end operational support from ideation through growth. The studio takes equity stakes in the resulting companies and captures returns via follow-on funding rounds, M&A exits, and potential IPOs.
Is AION Labs a public or private company?
AION Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was AION Labs founded?
AION Labs was founded in 2021. It employs 1 to 10 people.
Where is AION Labs based?
AION Labs is headquartered in Rehovot, Israel, in the Middle East region.
How does AION Labs make money?
Two revenue lines are on record. Equity stakes in portfolio companies are the primary driver. The others are strategic partnership fees.
Who are AION Labs's main competitors?
Direct peers on record are IndieBio, Petri (SRI International) and BioMed X. Broad incumbents are Flagship Pioneering, Insitro and Recursion Pharmaceuticals. Israel Biotech Fund is listed as a regional player. Emerging players are Celsius Therapeutics, Atomwise and Xaira Therapeutics.
Does AION Labs have an API?
No public API is recorded for AION Labs.
What industry is AION Labs in?
AION Labs's product category is Pharmaceutical AI Venture Studio / Biotech Incubation. Its primary akta.pro industry code is FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.